• 1
    Fruhwald MC, O'Dorisio MS, Pietsch T, Reubi JC. High expression of somatostatin receptor subtype 2 (sst2) in medulloblastoma: implications for diagnosis and therapy. Pediatr Res. 1999; 45(5 Pt 1): 697708.
  • 2
    Kortmann RD, Kuhl J, Timmermann B, et al. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT '91. Int J Radiat Oncol Biol Phys. 2000; 46: 269279.
  • 3
    Reubi JC, Kappeler A, Waser B, et al. Immunohistochemical localization of somatostatin receptors sst2A in human tumors. Am J Pathol. 1998; 153: 233245.
  • 4
    Merlo A, Hausmann O, Wasner M, et al. Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): a pilot study in human gliomas. Clin Cancer Res. 1999; 5: 10251033.
  • 5
    Bouffet E. Embryonal tumours of the central nervous system. Eur J Cancer. 2002; 38: 11121120.
  • 6
    Silverman CL, Palkes H, Talent B, et al. Late effects of radiotherapy on patients with cerebellar medulloblastoma. Cancer. 1984; 54: 825829.
  • 7
    Packer RJ, Sposto R, Atkins TE, et al. Quality of live in children with primitive neuroectodermal tumors (medulloblastoma) of the posterior fossa. Pediatr Neurosci. 1987; 13: 169175.
  • 8
    Ris MD, Packer R, Goldwein J et al. Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children's Cancer Group study. J Clin Oncol. 2001; 19: 34703476.
  • 9
    Taylor RE, Bailey CC, Robinson K., et al. Results of a randomised study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: the International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 Study. J Clin Oncol. 2003; 21: 15811591.
  • 10
    Bailey CC, Gnekow A, Wellek S, et. al. Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Pediatric Oncology (SIOP) and the (German) Society of Pediatric Oncology (GPO): SIOP II. Med Pediatr Oncol. 1995; 25: 166178.
  • 11
    Evans AE, Jenkin RDT, Sposto R, et al. The treatment of medulloblastoma: results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine and prednisone. J Neurosurg. 1990; 72: 572582.
  • 12
    Zia MI, Forsyth P, Chaudhry A, et al. Possible benefits of high-dose chemotherapy and autologous stem cell transplantation for adults with recurrent medulloblastoma. Bone Marrow Transplant. 2002; 30: 565569.
  • 13
    Albright AL, Wisoff JH, Zeltzer PM, et al. Effects of medulloblastoma resections on outcome in children: a report from the Children's Cancer Group. Neurosurgery. 1996; 38: 265271.
  • 14
    Heppeler A, Froidevaux S, Maecke HR, et al. Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy. Chem Eur J. 1999; 5: 19741981.
  • 15
    Vaidyanathan G, Friedman HS, Affleck DJ, et al. Specific and high-level targeting of radiolabeled octreotide analogues to human medulloblastoma xenografts. Clin Cancer Res. 2003; 9: 18681876.
  • 16
    Waldherr C, Pless M, Maecke HR, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq 90Yttrium-DOTATOC. J Nucl Med. 2002; 43: 610616.
  • 17
    Otte A, Mueller-Brand J, Dellas S, et al. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet. 1998; 351: 417418.
  • 18
    Schumacher T, Hofer S, Eichhorn K, et al. Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO Grades II an III: an extended pilot study. Eur J Nucl Med Mol Imaging. 2002; 29: 486493.
  • 19
    Hofer S, Eichhorn K, Freitag P, et al. Successful diffusible brachytherapy (dBT) of a progressive low-grade astrocytoma using the locally injected peptidic vector and somatostatin analogue [90Y]-DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC). Swiss Med Wkly. 2001; 131(43–44): 640644.
  • 20
    Merlo A, Mueller-Brand J, Maecke HR. Comparing monoclonal antibodies and small peptidic hormones for local targeting of malignant gliomas. Acta Neurochir. 2003; 88( Suppl): 8391.
  • 21
    Finlay JL. The role of high-dose chemotherapy and stem cell rescue in the treatment of malignant brain tumors [review]. Bone Marrow Transplant. 1996; 18( Suppl 3): S1S5.
  • 22
    Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999; 341: 11651173.
  • 23
    Michon J, Schleiermacher G. Autologous haematopoietic stem cell transplantation for paediatric solid tumors. Baillieres Best Pract Res Clin Haematol. 1999; 12(1–2): 247259.
  • 24
    Dupuis-Girod S, Hartmann O, Behamou E et al. High-dose chemotherapy in relapse of medulloblastoma in young children [review] [in French]. Bull Cancer. 1997; 84: 264272.
  • 25
    Strother D, Ashley D, Kellie SJ, et al. Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study. J Clin Oncol. 2001; 19: 26962704.